Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting Contraception Four Commercially Available Solutions for Women on the Horizon Conference Call Today at 4:30 p.m. ET Q2 2025 Highlights; Near-Term Revenue and Long-Term Value Creation Through Dual-Path Execution: Sildenafil Cream, 3.6% DARE-HPV and DARE-LARC1: Progress in Grant-Funded Women's Health Innovation Ongoing Actions to Make Three Additional Solutions Available Commercially DARE to PLAY™ Sildenafil Cream on Track for Q4 ...